Zheng Quan Zhi Xing·2025-05-14 08:26Group 1 - The core point of the announcement is that Shanghai Pharmaceuticals has received approval from the National Medical Products Administration for the production of its product, Wengjing Decoction Granules [1][2] - The product is classified as a traditional Chinese medicine and is registered under category 3.1, with a specification of 20g per bag [1] - The formulation of Wengjing Decoction Granules is derived from a historical text and is indicated for treating menstrual irregularities and abdominal pain in women [1] Group 2 - The company has invested approximately RMB 4.69 million in the research and development of this product [1] - The approval is expected to enhance the market competitiveness of the company and provide valuable experience for future research and registration of traditional Chinese medicine compound preparations [2] - As of the announcement date, there are no procurement data available for this product in Chinese hospitals for 2024 according to the IQVIA database [2]